Literature DB >> 11050106

Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus.

H Awad1, G W Hubert, Y Smith, A I Levey, P J Conn.   

Abstract

The subthalamic nucleus (STN) is a key nucleus in the basal ganglia motor circuit that provides the major glutamatergic excitatory input to the basal ganglia output nuclei. The STN plays an important role in normal motor function, as well as in pathological conditions such as Parkinson's disease (PD) and related disorders. Development of a complete understanding of the roles of the STN in motor control and the pathophysiological changes in STN that underlie PD will require a detailed understanding of the mechanisms involved in regulation of excitability of STN neurons. Here, we report that activation of group I metabotropic glutamate receptors (mGluRs) induces a direct excitation of STN neurons that is characterized by depolarization, increased firing frequency, and increased burst-firing activity. In addition, activation of group I mGluRs induces a selective potentiation of NMDA-evoked currents. Immunohistochemical studies at the light and electron microscopic levels indicate that both subtypes of group I mGluRs (mGluR1a and mGluR5) are localized postsynaptically in the dendrites of STN neurons. Interestingly, pharmacological studies suggest that each of the mGluR-mediated effects is attributable to activation of mGluR5, not mGluR1, despite the presence of both subtypes in STN neurons. These results suggest that mGluR5 may play an important role in the net excitatory drive to the STN from glutamatergic afferents. Furthermore, these studies raise the exciting possibility that selective ligands for mGluR5 may provide a novel approach for the treatment of a variety of movement disorders that involve changes in STN activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050106      PMCID: PMC6772731     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  54 in total

1.  Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones.

Authors:  A Pisani; P Calabresi; D Centonze; G Bernardi
Journal:  Br J Pharmacol       Date:  1997-03       Impact factor: 8.739

2.  Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis.

Authors:  J Guridi; M T Herrero; M R Luquin; J Guillén; M Ruberg; J Laguna; M Vila; F Javoy-Agid; Y Agid; E Hirsch; J A Obeso
Journal:  Brain       Date:  1996-10       Impact factor: 13.501

3.  Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.

Authors:  J A Monn; M J Valli; S M Massey; R A Wright; C R Salhoff; B G Johnson; T Howe; C A Alt; G A Rhodes; R L Robey; K R Griffey; J P Tizzano; M J Kallman; D R Helton; D D Schoepp
Journal:  J Med Chem       Date:  1997-02-14       Impact factor: 7.446

Review 4.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

5.  CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.

Authors:  S Litschig; F Gasparini; D Rueegg; N Stoehr; P J Flor; I Vranesic; L Prézeau; J P Pin; C Thomsen; R Kuhn
Journal:  Mol Pharmacol       Date:  1999-03       Impact factor: 4.436

6.  Metabotropic glutamate agonist-induced rotation: a pharmacological, FOS immunohistochemical, and [14C]-2-deoxyglucose autoradiographic study.

Authors:  J A Kearney; K A Frey; R L Albin
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

7.  Heterogeneity of metabotropic glutamate receptors in the striatum: electrophysiological evidence.

Authors:  P Calabresi; A Pisani; N B Mercuri; G Bernardi
Journal:  Eur J Neurosci       Date:  1993-10-01       Impact factor: 3.386

8.  Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys.

Authors:  A Benazzouz; C Gross; J Féger; T Boraud; B Bioulac
Journal:  Eur J Neurosci       Date:  1993-04-01       Impact factor: 3.386

9.  The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.

Authors:  H Bergman; T Wichmann; B Karmon; M R DeLong
Journal:  J Neurophysiol       Date:  1994-08       Impact factor: 2.714

10.  Differential loss of striatal projection neurons in Huntington disease.

Authors:  A Reiner; R L Albin; K D Anderson; C J D'Amato; J B Penney; A B Young
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

View more
  132 in total

1.  Interactions between adenosine and metabotropic glutamate receptors in the rat hippocampal slice.

Authors:  Ali Shahraki; Trevor W Stone
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

2.  Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal.

Authors:  Astrid K Stoker; Berend Olivier; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2011-12-03       Impact factor: 4.530

Review 3.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

4.  Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats.

Authors:  Nathalie Breysse; Marianne Amalric; Pascal Salin
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

5.  A model of atropine-resistant theta oscillations in rat hippocampal area CA1.

Authors:  M J Gillies; R D Traub; F E N LeBeau; C H Davies; T Gloveli; E H Buhl; M A Whittington
Journal:  J Physiol       Date:  2002-09-15       Impact factor: 5.182

6.  Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function.

Authors:  Meredith J Noetzel; Jerri M Rook; Paige N Vinson; Hyekyung P Cho; Emily Days; Y Zhou; Alice L Rodriguez; Hilde Lavreysen; Shaun R Stauffer; Colleen M Niswender; Zixiu Xiang; J Scott Daniels; Carrie K Jones; Craig W Lindsley; C David Weaver; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2011-10-21       Impact factor: 4.436

7.  Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade.

Authors:  Mark R Stefani; Bita Moghaddam
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

Review 8.  Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.

Authors:  M Foster Olive
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

Review 9.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

10.  Different metabotropic glutamate receptors play opposite roles in synaptic plasticity of the rat medial vestibular nuclei.

Authors:  Silvarosa Grassi; Adele Frondaroli; Vito Enrico Pettorossi
Journal:  J Physiol       Date:  2002-09-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.